|
Final results from the CAVE (cetuximab rechallenge plus avelumab) mCRC phase II trial: Skin toxicity as a predictor of clinical activity. |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
Honoraria - BMS; Merck; MSD; Pfizer; Roche; Sanofi; SERVIER |
Consulting or Advisory Role - Bristol-Myers Squibb; EMD SERONO; Incyte; Nerviano Medical Sciences; Novartis Italy; Roche; Sanofi; Teofarma |
Research Funding - Kymab (Inst); Loxo (Inst); Merck Serono (Inst); Nerviano Medical Sciences (Inst); Novartis (Inst); Pfizer (Inst); Philogen (Inst); Roche (Inst); SERVIER (Inst); Tesaro (Inst) |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
Consulting or Advisory Role - Biocartis |
|
| |
|
Consulting or Advisory Role - Amgen; SERVIER |
Speakers' Bureau - Amgen; SERVIER |
| |
|
No Relationships to Disclose |
| |
|
Travel, Accommodations, Expenses - Merck Serono |
| |
|
Honoraria - Amgen; Lilly; Merck; Roche; SERVIER |
Consulting or Advisory Role - Amgen; Bayer; Bristol-Myers Squibb; Lilly; Merck; Roche; SERVIER |
Research Funding - Amgen (Inst); Bayer (Inst); Merck (Inst); MSD (Inst); Roche (Inst); Sanofi (Inst); SERVIER (Inst) |
Travel, Accommodations, Expenses - Amgen; Bayer; Merck; Roche; SERVIER |
| |
|
Consulting or Advisory Role - Amgen/Dompé; Merck Serono; SERVIER |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
Consulting or Advisory Role - Bayer; Merck Serono; Novartis; Roche; Sanofi; SERVIER |
Speakers' Bureau - Bayer; Merck Serono; Novartis; Roche; Sanofi; SERVIER |
| |
|
No Relationships to Disclose |